BOSTON / Jan 11, 2024 / Business Wire / Verastem Oncology (Nasdaq: VSTM) (the “Company), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on Thursday, January 18, 2024 at 4:00 p.m. ET.
To access the live webcast of the fireside chat, please contact your B. Riley Securities sales representative.
Following the event, an archived replay of the fireside chat will be available on the investors section of the Company’s website at www.verastem.com.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
| Last Trade: | US$4.06 |
| Daily Change: | -0.07 -1.69 |
| Daily Volume: | 52,316 |
| Market Cap: | US$163.370M |
November 06, 2024 September 10, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
